Inclusion Criteria:

          -  Must be able to provide written informed consent before any screening procedures.

          -  Male or female patients ≥18 years of age.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          -  Patients with a confirmed diagnosis of multiple myeloma who have received two or more
             lines of therapy including an IMiD and PI, and are relapsed and/or refractory to their
             most recent line of therapy. Patients who have received a prior autologous bone marrow
             transplant and otherwise meet the inclusion criteria are eligible for this study.

          -  Must have measurable disease defined by at least 1 of the following 3 measurements:

          -  Serum M-protein ≥ 0.5 g/dL OR

          -  Urine M-protein ≥ 200 mg/24 hours OR

          -  Serum free light chain (FLC) > 100 mg/L of involved FLC

          -  All patients must be willing to undergo a mandatory serial bone marrow aspirate and/or
             biopsy at screening and subsequently following treatment for the assessment of
             biomarker/pharmacodynamics and disease status. Exceptions may be considered after
             documented discussion with Novartis.

        Other inclusion criteria included in the protocol might apply.

        Exclusion Criteria:

          -  Use of systemic chronic steroid therapy (≥10mg /day of prednisone or equivalent), or
             any immunosuppressive therapy within 7 days of first dose of study treatment. Topical,
             inhaled, nasal, or ophthalmic steroids are allowed.

          -  Malignant disease, other than that being treated in this study. Exceptions to this
             exclusion include the following: malignancies that were treated curatively and have
             not recurred within 2 years prior to study treatment; completely resected basal cell
             and squamous cell skin cancers, and completely resected carcinoma in situ of any type.

          -  Active, known or suspected autoimmune disease other than patients with vitiligo,
             residual hypothyroidism only requiring hormone replacement, psoriasis not requiring
             systemic treatment or conditions not expected to recur.

          -  Patients with prior known toxicity attributed to PD-1 or PDL-1 directed therapy, which
             led to discontinuation of these agents, will be excluded from the PDR001 containing
             arms of the study.

          -  Patients with prior known toxicity from IL-17A directed therapy, which led to
             discontinuation of the study treatment, will be excluded from CJM112 containing arms
             of the study.

          -  Any of the following clinical laboratory results during screening (i.e., within 28
             days before the first dose of study treatment):

               -  Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within
                  7 days prior to testing

               -  Platelet count < 75,000 mm3 without transfusion support within 7 days prior to
                  testing

               -  Bilirubin > 1.5 times the upper limit of the normal range (ULN)

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the
                  ULN

               -  Calculated creatinine clearance < 30 ml/min according to Cockcroft-Gault equation
                  Other exclusion criteria included in the protocol might apply.